Clinical trial
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide…
NCT02252172 · Janssen Research & Development, LLC, Industry · Completed
Key facts
| NCT number | NCT02252172 |
|---|---|
| Title | Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma |
| Official title | A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy |
| Lead sponsor | Janssen Research & Development, LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Daratumumab IV, Lenalidomide, Dexamethasone, Daratumumab SC |
| Enrollment | 737 |
| Start date | Feb 16, 2015 |
| Primary completion | Sep 24, 2018 |
| Completion | Oct 2, 2024 |
| First posted | Sep 30, 2014 |
| Last update posted | Oct 20, 2025 |
| Countries | Australia, Austria, Belgium, Canada, Denmark, France, Germany, Ireland, Israel, Netherlands, Sweden, United Kingdom and 1 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: